New combo tackles tough lymphoma after other treatments fail
NCT ID NCT06192888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether combining glofitamab (an IV drug) with lenalidomide (an oral drug) is a feasible treatment for people with mantle cell lymphoma that has returned or not responded to prior therapy, including a BTK inhibitor. The study enrolls 39 adults and focuses on whether participants can complete the first three treatment cycles without major delays. It is an early-stage trial, so the main goal is to assess feasibility, not yet to confirm effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glofitamab (given by IV) and lenalidomide (taken by mouth)
What this could lead to
If this combination works, it could offer a new treatment option for people with mantle cell lymphoma that has come back after other therapies.
What could go wrong
This is a very early, small Phase 1 pilot study with only 39 participants. It is designed mainly to see if the treatment is feasible, not yet to prove it works. Side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute (Data Collection and Specimen Analysis)
Boston, Massachusetts, 02115, United States
-
Mayo Clinic (Data Collection Only)
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604, United States
-
Washington University (Data Collection Only)
St Louis, Missouri, 63110, United States